Capsular polysaccharide solubilisation and combination vaccines
AssigneeGlaxosmithkline Biologicals SA
InventorPaolo Costantino
Life of this patent
Estimating the term…
Abstract
Precipitated bacterial capsular polysaccharides can be efficiently re-solubilised using alcohols as solvents. The invention provides a process for purifying a bacterial capsular polysaccharide, comprising the steps of (a) precipitation of said polysaccharide, followed by (b) solubilisation of the precipitated polysaccharide using ethanol. CTAB can be used for step (a). The material obtained, preferably following hydrolysis and sizing, can be conjugated to a carrier protein and formulated as a vaccine. Also, in vaccines comprising saccharides from both serogroups A and C, the invention provides that the ratio (w/w) of Men A saccharide:MenC saccharide is >1.
Claims9
A liquid composition comprising a Neisseria meningitidis serogroup A capsular saccharide conjugate and a Neisseria meningitidis serogroup C capsular saccharide conjugate, and further comprising (i) an aluminum hydroxide adjuvant and (ii) a histidine buffer, and where each conjugate has a saccharide:protein ratio (w/w) of between 0.5:1 and 5:1.
Dependencies are inferred from the claim text.